After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Zimmer's return to growth is fueling acquisition thoughts by analysts. There are a number of possibilities.
Zimmer Biomet is on track to return to growth, which could signal more mergers and acquisitions within the industry.
Merck stock has not moved higher. Now is the time to buy.
The company's hepatitis C drug division is expected to see losses in the second half of the year.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.